Arcturus’ COVID-19 Vaccine Phase 3 Study Shows Promising Results
San Diego, Calif.-based Arcturus Therapeutics said that its messenger RNA (mRNA) vaccine has demonstrated strong protection against COVID-19 in a large late-stage study.
The phase 3 trial in Vietnam enrolled more than 16,000 participants. Two doses of the company’s ARCT-154 COVID-19 vaccine showed 55 percent efficacy in preventing COVID-19 infection and 95 percent efficacy at preventing severe COVID-19 disease, the company said.
Arcturus said it is working with the FDA, the European Medicines Agency and the UK’s Medicines and Healthcare products Regulatory Agency to get the vaccine approved.